1. Home
  2. TALO vs MIRM Comparison

TALO vs MIRM Comparison

Compare TALO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Talos Energy Inc.

TALO

Talos Energy Inc.

HOLD

Current Price

$16.58

Market Cap

2.7B

Sector

Energy

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$88.24

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TALO
MIRM
Founded
2011
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
5.4B
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
TALO
MIRM
Price
$16.58
$88.24
Analyst Decision
Buy
Strong Buy
Analyst Count
4
12
Target Price
$69.50
$114.67
AVG Volume (30 Days)
2.3M
806.2K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
74.59
EPS
N/A
N/A
Revenue
$1,780,070,000.00
$19,138,000.00
Revenue This Year
N/A
$26.22
Revenue Next Year
$2.63
$21.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.23
$36.88
52 Week High
$17.01
$109.28

Technical Indicators

Market Signals
Indicator
TALO
MIRM
Relative Strength Index (RSI) 74.30 43.42
Support Level $10.49 $85.76
Resistance Level N/A $96.65
Average True Range (ATR) 0.58 3.59
MACD 0.26 -0.15
Stochastic Oscillator 87.23 29.33

Price Performance

Historical Comparison
TALO
MIRM

About TALO Talos Energy Inc.

Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. Its revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: